Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 6/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270130 | 0.83 | NT5E (0.48) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL30021963 | 0.81 | HTR1A (0.47) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL28516241 | 0.80 | PTPN1 (0.50) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL20473776 | 0.80 | PTPN1 (0.50) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL1550942 | 0.80 | SLC5A2 (0.46) | PTPN1TACR2NT5EBCHE | |
| SCHEMBL2575933 | 0.79 | HTR1A (0.45) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL5207672 | 0.79 | NT5E (0.55) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL7151712 | 0.79 | TACR2 (0.51) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL2579063 | 0.78 | HTR1A (0.44) | PTPN1TACR2NT5ECDC25BSSTR1 | |
| SCHEMBL5273546 | 0.78 | NT5E (0.48) | PTPN1TACR2NT5ECDC25BSSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | PTPN1 215/4885TACR2 1661/4885NT5E 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.